Today’s weight-loss injections that reach millions typically act at the cell surface: a molecule attaches to a receptor, the receptor sends a signal, and the medicine itself never needs to enter the cell.
A research team in Germany revisited those same receptors and focused on something others had largely overlooked.
Receptor binding doesn’t just switch on signalling; it can also prompt the cell to draw the bound compound inside.
A second passenger
That idea emerged from the laboratory led by Professor Timo D. Müller, Director of the Institute for Diabetes and Obesity at Helmholtz Munich, where researchers investigate how the body regulates fuel use.
The injections most people recognise are built around incretin hormones-gut-derived messengers released after eating that curb appetite and help keep blood sugar stable.
Two incretins, GLP-1 and GIP, drive much of that effect. Müller’s group set out to pair that incretin activity with a second, more potent medicine.
The add-on drug activates a family of regulatory proteins involved in controlling fat burning and the way the body processes sugar.
Because these controls are present in almost all tissues, stimulating them broadly can trigger damage where the effect is not wanted.
In an earlier study, the team had already demonstrated an approach that lets a gut hormone deliver such a drug only to the appropriate locations.
Targeting the right cells
For the latest molecule, the researchers chemically linked lanifibranor-a drug being tested for fatty liver disease-directly to an incretin compound. They described the concept as an “address label with cargo.”
The incretin portion attaches to GLP-1 or GIP receptors on the surface of particular cells. After binding, the cell seems to internalise the entire complex, allowing the second drug to be released to act inside.
By restricting activity to cells that carry those receptors, the team used only a fraction of a typical dose-nearly 7,000 times less than standalone versions require-leaving far less free drug circulating around the body.
Better than today’s drugs
In mice made heavier by a high-calorie diet, the hybrid outperformed existing options. Compared with semaglutide, it drove larger weight loss, reduced food intake more, and lowered blood sugar further.
It also beat a dual agent designed to mimic both GLP-1 and GIP simultaneously-an approach that had already surpassed semaglutide in a human trial.
Even against that stronger comparator, the hybrid still produced greater weight loss. The added benefit was not explained by higher energy expenditure or increased movement.
Instead, the mice ate less, and their weight continued to drop after the comparison treatments had plateaued.
A benefit beyond weight
One finding was notable because it went beyond what the older drugs could deliver. The team asked whether improved blood sugar control came purely from reduced body fat, or whether the hybrid produced an additional direct effect.
To test this, they designed a tightly controlled experiment: one group received the hybrid and another received the two-hormone drug, while food was rationed so that both groups ended at exactly the same body weight.
Although weight was matched, blood sugar was not.
The hybrid-treated mice still processed glucose more effectively and showed lower fasting blood sugar than their weight-matched counterparts.
This points to a genuine improvement in insulin sensitivity rather than an indirect consequence of weight loss. In the liver, the hybrid also reduced inflammation that underlies much of the harm associated with obesity.
Sidestepping the effects
When given by itself, lanifibranor is associated with substantial side effects. In a human trial for liver disease, it benefited the liver but patients gained weight and developed fluid retention.
The targeted hybrid avoided these problems: there was no extra weight gain, no anaemia, no fluid build-up, and no kidney damage.
In other words, it did not produce the liabilities seen when lanifibranor is administered without a targeting mechanism.
The mice also showed better cardiac function, with stronger pumping performance and less obesity-related swelling.
A conventional version promotes weight gain in part by driving the formation of new fat cells, and the targeted approach bypassed that pathway entirely.
Proof it stays targeted
To confirm the design truly depended on GLP-1 or GIP receptors, the researchers used mice engineered to lack those receptors.
In those animals, the hybrid had little effect-no meaningful weight loss and no reduction in blood sugar.
They also performed the reverse test. When they blocked one of the cellular controls that lanifibranor was intended to activate, the blood-sugar advantage disappeared while the weight-loss effect remained.
Lean, healthy mice provided another safeguard: the hybrid did not change their weight or blood sugar.
This suggests it acts where dysfunction exists, rather than pushing healthy physiology below normal.
Future action items
The central message is straightforward: a single molecule can be used to ferry a powerful drug into only the cells meant to receive it.
In mice, the approach exceeded leading obesity treatments while avoiding the side effects typically associated with lanifibranor, and it delivered blood-sugar improvements that were not explained by weight loss alone.
These are benefits that current obesity drugs have not shown consistently in mouse studies.
The delivery strategy itself could be reused more broadly, using the same principle to direct other medicines to other cell types.
For now, the work remains limited to mice, and converting a laboratory construct into an approved medicine would take years as well as well-funded partners.
Even so, it offers drug developers a fresh route for steering existing drugs towards cells where they are beneficial, while limiting exposure in tissues where they could do harm.
Comments
No comments yet. Be the first to comment!
Leave a Comment